Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that its CEO, Michael Halstead, will participate in a fireside chat at the Cantor Global Healthcare Conference, scheduled for September 9-11, 2026, in New York City. The fireside chat will be webcast live on September 11 at 8:00 a.m. EDT, with a replay available on the company's investor relations website.
This participation comes at a critical time for the company, which is advancing a pipeline of proprietary NSAs designed to activate serotonin pathways believed to promote neuroplasticity. These synthetic molecules aim to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder.
The company's commitment to innovation is reflected in its extensive research portfolio of investigational NSAs. With class-leading data, Helus Pharma aims to improve the treatment landscape by introducing therapies that provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland, and its commercial name, Helus Pharma, is a trademark of Cybin Corp.
The upcoming fireside chat at the Cantor conference provides an opportunity for investors and industry stakeholders to gain insights into the company's strategic direction and clinical progress. This event underscores the growing interest in psychedelic-inspired treatments and the potential of NSAs to revolutionize mental health care. As the global burden of mental health disorders continues to rise, the development of effective and durable treatments is paramount. Helus Pharma's focus on neuroplasticity and serotonin modulation represents a promising avenue for addressing conditions like major depressive disorder, which affects millions worldwide.
The company's participation in such a prominent healthcare conference also signals its commitment to engaging with the investment community and advancing its pipeline. The webcast will allow a broader audience to hear directly from the CEO about the latest developments and future milestones.
For more information about Helus Pharma and its ongoing efforts, interested parties are encouraged to visit the company's website or follow its updates on social media platforms. The full press release regarding the conference participation is available at this link. Additionally, the latest news and updates relating to the company can be found in its newsroom at IBN's HELP newsroom.
The Cantor Global Healthcare Conference is a key event for the healthcare investment community, bringing together industry leaders, innovators, and investors. Helus Pharma's presence at the conference highlights the increasing relevance of psychedelic-derived therapies in mainstream medicine. As the company progresses its clinical trials, the outcomes could have significant implications for patients, healthcare providers, and the pharmaceutical industry at large.
